La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Synlogic Croissance future

Future contrôle des critères 0/6

Le chiffre d'affaires de Synlogic devrait diminuer de 122.1% par an, tandis que ses bénéfices annuels devraient croître de 86% par an. Le BPA devrait croître de , augmenter de 89.8% par an.

Informations clés

86.0%

Taux de croissance des bénéfices

89.8%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.5%
Taux de croissance des recettes	-122.1%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	16 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Synlogic gets milestone payment under Roche pact to discover synthetic biotic for bowel disease

Sep 06

Synlogic's metabolic disorder drug gets FDA fast track status

Aug 23

Synlogic Q2 2022 Earnings Preview

Aug 10

Is Synlogic (NASDAQ:SYBX) In A Good Position To Invest In Growth?

Aug 09

Synlogic begins dosing in early-stage trial of SYNB1353 for rare metabolic disorder

Jul 12

Here's Why We're Watching Synlogic's (NASDAQ:SYBX) Cash Burn Situation

Jan 11

Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth

Sep 28

Synlogic (SYBX) Investor Presentation - Slideshow

Jun 08

Here's Why We Think Synlogic, Inc.'s (NASDAQ:SYBX) CEO Compensation Looks Fair

Jun 03

Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth

Feb 23

Synlogic (NASDAQ:SYBX) Share Prices Have Dropped 67% In The Last Three Years

Jan 19

Synlogic outlines clinical milestones for 2021

Jan 11

Our Take On Synlogic's (NASDAQ:SYBX) CEO Salary

Dec 15

Synlogic, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

Synlogic EPS beats by $0.10

Nov 05

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:SYBX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	N/A	-3	N/A	N/A	1
12/31/2025	N/A	-6	N/A	N/A	1
12/31/2024	N/A	-33	N/A	N/A	1
6/30/2024	3	-56	-49	-49	N/A
3/31/2024	3	-73	-46	-46	N/A
12/31/2023	3	-57	-52	-52	N/A
9/30/2023	1	-59	-59	-58	N/A
6/30/2023	1	-65	-61	-61	N/A
3/31/2023	1	-66	-63	-63	N/A
12/31/2022	1	-66	-58	-57	N/A
9/30/2022	2	-65	-58	-58	N/A
6/30/2022	2	-63	-57	-56	N/A
3/31/2022	2	-61	-55	-54	N/A
12/31/2021	2	-61	-53	-52	N/A
9/30/2021	1	-60	-50	-49	N/A
6/30/2021	0	-57	-44	-43	N/A
3/31/2021	0	-58	-41	-41	N/A
12/31/2020	1	-59	-40	-40	N/A
9/30/2020	2	-57	-42	-41	N/A
6/30/2020	2	-57	-44	-43	N/A
3/31/2020	2	-54	-76	-75	N/A
12/31/2019	2	-51	-77	-75	N/A
9/30/2019	1	-51	-75	-73	N/A
6/30/2019	3	-48	-76	-72	N/A
3/31/2019	3	-50	-47	-43	N/A
12/31/2018	3	-48	-48	-42	N/A
9/30/2018	3	-48	-47	-43	N/A
6/30/2018	1	-49	-45	-40	N/A
3/31/2018	3	-44	N/A	-37	N/A
12/31/2017	2	-40	N/A	-31	N/A
9/30/2017	2	-36	N/A	-29	N/A
6/30/2017	2	-29	N/A	-26	N/A
3/31/2017	0	-24	N/A	-23	N/A
12/31/2016	0	-21	N/A	-20	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: SYBX devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: SYBX devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: SYBX devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: SYBX ne devrait pas générer de revenus l'année prochaine.

Croissance élevée des revenus: SYBX ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de SYBX devrait être élevé dans 3 ans

Synlogic Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 96% to US$1.00

Consensus revenue estimates increase by 747%

Consensus EPS estimates upgraded to US$11.03 loss

Price target decreased by 11% to US$5.00

Consensus revenue estimates increase by 11%, EPS downgraded

Consensus EPS estimates fall by 11%

Recent updates

New major risk - Financial position

Second quarter 2024 earnings released: EPS: US$0.17 (vs US$3.21 loss in 2Q 2023)

New major risk - Financial position

First quarter 2024 earnings released: US$2.60 loss per share (vs US$3.39 loss in 1Q 2023)

Price target decreased by 96% to US$1.00

Cable Car Capital Discloses its Views on Synlogic

Synlogic, Inc. Announces Departure of Aoife Brennan as Chief Executive Officer

Synlogic, Inc. Announces Departure of Aoife Brennan as President

Synlogic, Inc. Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Companies Like Synlogic (NASDAQ:SYBX) Could Be Quite Risky

Synlogic, Inc. Appoints Chief Financial Officer Changes, Effective December 1, 2023

Consensus revenue estimates increase by 747%

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

New major risk - Shareholder dilution

Consensus EPS estimates upgraded to US$11.03 loss

New major risk - Revenue and earnings growth

Can Synlogic (NASDAQ:SYBX) Afford To Invest In Growth?

Price target decreased by 11% to US$5.00

Synlogic, Inc. Announces Implementation of Reduction in Workforce

Synlogic, Inc. Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria

Consensus revenue estimates increase by 11%, EPS downgraded

We're A Little Worried About Synlogic's (NASDAQ:SYBX) Cash Burn Rate

Consensus EPS estimates fall by 11%

Synlogic, Inc. Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria

Synlogic, Inc. Appoints Dave Hava as Head of Research and Development

Synlogic Receives Non-Compliance Notice From Nasdaq

Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update

Here's Why We're Watching Synlogic's (NASDAQ:SYBX) Cash Burn Situation

Consensus forecasts updated

Synlogic Therapeutics: SYNB1934 Advances To Phase 3

Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU) SYNB1934 Advances to Phase 3

Synlogic gets milestone payment under Roche pact to discover synthetic biotic for bowel disease

Synlogic's metabolic disorder drug gets FDA fast track status

Synlogic, Inc Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

Synlogic Q2 2022 Earnings Preview

Is Synlogic (NASDAQ:SYBX) In A Good Position To Invest In Growth?

Synlogic, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Synlogic, Inc. Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria

Synlogic begins dosing in early-stage trial of SYNB1353 for rare metabolic disorder

Synlogic, Inc. Announces Appointment of Brendan St. Amant as Corporate Secretary, Effective July 1, 2022

Consensus forecasts updated

Synlogic, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$8.00

Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs At the Society for Inherited Metabolic Disorders 43Rd Annual Meeting

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer

Here's Why We're Watching Synlogic's (NASDAQ:SYBX) Cash Burn Situation

Price target decreased to US$9.00

Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth

Price target increased to US$10.00

Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting

Consensus revenue estimates increase to US$389.7k

Chief Medical Officer Richard Riese has left the company

Synlogic Announces Initiation of Phase 1 Study of SYNB1934 for treatment of Phenylketonuria

Synlogic, Inc. Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

Independent Director Chau Khuong has left the company

Synlogic (SYBX) Investor Presentation - Slideshow

Here's Why We Think Synlogic, Inc.'s (NASDAQ:SYBX) CEO Compensation Looks Fair

Synlogic, Inc. Provides Update on its Clinical and Preclinical Programs

Full year 2020 earnings released: US$1.65 loss per share (vs US$1.70 loss in FY 2019)

Price target increased to US$10.00

Synlogic, Inc. to Report Q4, 2020 Results on Mar 25, 2021

Synlogic, Inc Announces Promotion of Dr. Caroline Kurtz to Chief Development Officer

Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth

Synlogic Appoints Lisa Kelly-Croswell to Its Board of Directors

New 90-day high: US$4.90

Synlogic (NASDAQ:SYBX) Share Prices Have Dropped 67% In The Last Three Years

New 90-day high: US$3.18